about
Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's diseaseTrichloroethylene and parkinsonism: a human and experimental observationThe role of autonomic efferents and uncoupling protein 1 in the glucose-lowering effect of leptin therapyNeurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans.Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.Parkinson's disease: Exit toxins, enter geneticsEndogenous repair by the activation of cell survival signalling cascades during the early stages of rat Parkinsonism.Animal models of Parkinson's disease.Exposure to mitochondrial genotoxins and dopaminergic neurodegeneration in Caenorhabditis elegansOn the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons?Dopamine and the depressant action of morphine on stimulated guinea-pig ileum.The role of environmental exposures in neurodegeneration and neurodegenerative diseases.Classic and new animal models of Parkinson's disease.Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.Medaka fish Parkinson's disease modelNeurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.A rationale for the design of cell-specific toxic agents: the mechanism of action of 6-hydroxydopamine.Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine contentRole of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease.Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.Slowly progressive dopamine cell loss--a model on which to test neuroprotective strategies for Parkinson's disease?Detection of oxygen radicals in biological reactions.Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson's disease.Actinobacterial melanins: current status and perspective for the future.L-DOPA and graft-induced dyskinesia: different treatment, same story?Protective effects of Drynaria fortunei against 6-hydroxydopamine-induced oxidative damage in B35 cells via the PI3K/AKT pathway.Curcumin I mediates neuroprotective effect through attenuation of quinoprotein formation, p-p38 MAPK expression, and caspase-3 activation in 6-hydroxydopamine treated SH-SY5Y cells.Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells.Regeneration of dopaminergic neurons after 6-hydroxydopamine-induced lesion in planarian brain.Novel pathways in drug metabolism.The generation of hydroxyl radicals in biologic systems: toxicological aspects.Cytotoxic reactions of free radical species of oxygen.Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells.Effect of anoxic radiosensitizers on cellular and mitochondrial oxygen consumption and respiration control ratio.Structure-activity relationships of serotonin neurotoxins: effects on serotonin uptake.Structure-activity relationships in compounds analogous to 5,6-dihydroxytryptamine.Developmental plasticity of central serotonin neurons after 5,7-dihydroxytryptamine treatment.Mechanism of action of dihydroxytryptamines.Mechanisms of action of hydroxylated phenylethylamine and indoleamine neurotoxins.
P2860
Q27325407-C7FFB553-5CA0-46A1-99BF-2B80C9B438D3Q28371417-FF8B7834-1E06-4E93-86F8-BB692A945557Q28830375-23B3AAEC-F6B9-4BDE-84CB-219D102439D3Q30476174-A3C054C9-3CBF-4816-9E60-E8848C170E87Q30895929-9AE0ED98-E086-415B-813C-A27ACC4623D8Q34140428-29D56275-F305-4F06-A829-76A4BAF71BE8Q34516390-85038EBD-9F06-485B-B30C-5D7256600B19Q34596189-889E430E-BB20-4F59-BB86-B73DC02C5585Q34653802-2FA953E9-1782-416F-BEE9-0768BEA12C41Q34794235-141FBAB0-2FD2-43B4-8AA5-765FF7A9D831Q35176888-806F1E95-DC11-41C4-B7A7-0F43EC068B9AQ35551001-F46DEF21-7B26-4B13-B237-A35313186876Q35875871-452894D9-95F7-4E39-868F-9AA36155452EQ36030904-BC70ABAE-2633-4C97-904B-C18D077B2F50Q36267851-4A93F2EF-A11E-4B82-AD10-E6E1D5C2EDECQ36349458-892073BE-E135-441E-98DE-60A8AECAAEE2Q36356980-A5D1BC4B-C311-43A0-879A-A8B3D3E047D8Q36877695-639B65E4-24FB-4FBF-8733-9B4925960842Q37110410-C567BBD7-51CE-45BB-8007-327240769EFFQ37211755-59F2BB92-2BF0-4249-B25B-67A05ECA3888Q37602127-2447130A-BC1D-4046-B571-42A57B9B96C8Q37878246-61E0BA57-58C8-4A0E-A666-B53F7A67D322Q38046734-5566DE08-AF03-4BAC-95A1-E59456272F52Q38099783-11BBAB03-E651-42A5-B8EE-C16D914E7C35Q38119449-E8957537-50FA-4B7B-ADEE-BEFB450A219DQ38980421-E6CF89B0-7079-48BB-B226-3DD7AA8AEBACQ39125378-48558281-4151-42FE-94C2-2419565EE3A0Q39284027-03A79A57-F928-4C47-BB1B-44D902E7714BQ39651300-E950F81D-FA69-47B9-9C56-2A09E296A6C5Q39699314-55BD0A5F-16C0-4DD3-80E9-83F87B74BB1AQ39717481-28005800-6996-4E88-A964-69C828360824Q39783746-273CB1B8-04A3-4498-B990-DA7D693AD2CCQ40200709-445C2846-D505-4625-AF85-15625621E81CQ40309156-06C12357-99D9-40FC-9C94-AD251BF19530Q40544406-5C8E313A-8B17-4C9A-B00E-4DB0F5E113E2Q40560657-2015D372-9659-4B06-97DE-6204738DC0D6Q40560662-2FD96B9F-17FC-4A2E-94A0-DED9DA5B0707Q40560677-FE589DC3-C2B3-41FB-94CC-4C684907FC9CQ40560722-0AC53DEA-B187-4F0E-8B39-75518710AA1AQ40560743-50CD3022-2F68-4219-936C-9CA538A635C7
P2860
description
1975 nî lūn-bûn
@nan
1975 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年学术文章
@wuu
1975年学术文章
@zh-cn
1975年学术文章
@zh-hans
1975年学术文章
@zh-my
1975年学术文章
@zh-sg
1975年學術文章
@yue
name
Mechanisms of action of 6-hydroxydopamine.
@ast
Mechanisms of action of 6-hydroxydopamine.
@en
type
label
Mechanisms of action of 6-hydroxydopamine.
@ast
Mechanisms of action of 6-hydroxydopamine.
@en
prefLabel
Mechanisms of action of 6-hydroxydopamine.
@ast
Mechanisms of action of 6-hydroxydopamine.
@en
P1476
Mechanisms of action of 6-hydroxydopamine.
@en
P2093
P356
10.1016/0006-2952(75)90304-4
P407
P577
1975-01-01T00:00:00Z